Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.

نویسندگان

  • Cindy Varga
  • Wanling Xie
  • Jacob Laubach
  • Irene M Ghobrial
  • Elizabeth K O'Donnell
  • Matthew Weinstock
  • Claudia Paba-Prada
  • Diane Warren
  • Michelle E Maglio
  • Robert Schlossman
  • Nikhil C Munshi
  • Noopur Raje
  • Edie Weller
  • Kenneth C Anderson
  • Constantine S Mitsiades
  • Paul G Richardson
چکیده

Proteasome inhibitors (PI) and immunomodulatory agents (IMIDs) have improved the overall survival (OS) of patients with multiple myeloma (MM), but concerns have been raised about increased incidence of extramedullary disease (EMD) after the combined use of PIs and IMIDs for upfront therapy. We evaluated whether the addition of lenalidomide to bortezomib-based front-line regimens precipitated earlier development of EMD. We reviewed the charts of 117 MM patients (median follow-up from diagnosis 6·1 years; range 0·1-10·2 years) enrolled in eight clinical trials of first-line treatment with bortezomib-based regimens, with or without lenalidomide. We assessed development of EMD as extraosseous (distant from bone) or osseous (originating from bone) plasmacytomas. The primary endpoint was time from diagnosis until development of EMD, based on imaging, biopsy and/or physical examination. Any form of EMD at progression was observed in 40 (34·2%) patients, including 21 (18%) osseous, 8 (7%) extraosseous and 11 (9%) both osseous and extraosseous. Median OS was 0·9 years (range 0·1-4·8 years) after extraosseous EMD development. Sensitivity analyses with follow-up times truncated at 5 years detected no statistically significant difference in rates of any EMD form between the two groups (P > 0·2 for each comparison). Therefore, we observed no evidence that bortezomib-lenalidomide-based front-line therapy precipitates earlier EMD.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Multiple Myeloma Presenting as Respiratory Stridor

Extramedullary plasmacytoma occurs in 18% of patients with multiple myeloma. Laryngeal involvement in multiple myeloma is rare, and only a few cases have been reported. We present a case of a 44-year-old women with multiple myeloma who presented with stridor due to a mass involving the larynx which was initially proven to be plasmacytoma on biopsy. She had evidence of multiple myeloma of IgA la...

متن کامل

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

BACKGROUND Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response rates in multiple myeloma. However, most patients still relapse, indicating the need for novel combination partners to increase duration of response or to treat relapsed disease. We explored the antimyeloma activity of triple combinations of these well-established sch...

متن کامل

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.

Responses to treatment of relapsed and refractory multiple myeloma are characteristically short, and median survival is as brief as 6 months. Although prognostic factors in the context of relapsed and refractory disease require further characterization, high-risk patients include those with certain cytogenetic abnormalities, high beta2-microglobulin, and low serum albumin. The development of no...

متن کامل

Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents.

The introduction of stem cell transplantation and the novel anti-myeloma agents, bortezomib, thalidomide, and lenalidomide, have improved the outcome of patients with multiple myeloma. These advances have transformed myeloma into a chronic condition, with multiple relapses and salvage therapies, all of which result in cumulative immunosuppression and higher risk of infection. In addition to the...

متن کامل

Autologous stem cell transplantation for multiple myeloma: history and future

Over the last decade, high-dose therapy supported by autologous stem cell transplantation (ASCT) has been the standard frontline therapy for younger patients with multiple myeloma (MM). But recently, the treatment strategy has been dramatically changed after the introduction of novel agents such as thalidomide, bortezomib and lenalidomide. These agents have been incorporated into induction ther...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • British journal of haematology

دوره 169 6  شماره 

صفحات  -

تاریخ انتشار 2015